Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy

Peer Review reports

Original Submission
2 Sep 2013	Submitted	Original manuscript
3 Oct 2013	Reviewed	Reviewer Report - hecheng li
14 Oct 2013	Reviewed	Reviewer Report - Nitin Ohri
1 Dec 2013	Author responded	Author comments - Hiroaki Akamatsu
Resubmission - Version 2
1 Dec 2013	Submitted	Manuscript version 2
22 Dec 2013	Author responded	Author comments - Hiroaki Akamatsu
Resubmission - Version 3
22 Dec 2013	Submitted	Manuscript version 3
Publishing
9 Jan 2014	Editorially accepted
14 Jan 2014	Article published	10.1186/1471-2407-14-18

Back to article page